• About us
• Contact

Advertisement

Organisation › Details

H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with brain disorders. In 2010, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). *

 

	Start	1990-01-01 existent
	Group	Lundbeck (Group)
	Industry	pharmaceutical
	Industry 2	psychopharmaceutical
	Person	Dunsire, Deborah (Lundbeck 201809– CEO before XTuit Pharma + Forum/EnVivo Pharma + Millennium/Takeda)
	Person 2	Götzsche, Anders (Lundbeck 201309 CFO)
	Region	København (Copenhagen)
	Country	Denmark
	Street	9 Ottiliavej
	City	2500 Valby
	Tel	+45-3630-1311
		Address record changed: 2024-01-05
Basic data	Employees	G: 5,001 to 10,000 (2019-12-31)
	Currency	DKK
	Annual sales	17,036,000,000 (revenue, consolidated (2019) 2019-12-31)
	Profit	2,667,000,000 (2019-12-31)
	Cash	3,008,000,000 (2019-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Lundbeck (Group)

• [1] Lundbeckfonden. (10/16/23). "Press Release: Venture Forces Invest Millions in New Type of Treatment for Particularly Aggressive Form of Cancer"....
• [2] IO Biotech, Inc.. (8/7/23). "Press Release: IO Biotech, Inc. Announces $75 Million Private Placement Financing". New York, NY....
• [3] H. Lundbeck A/S. (4/8/22). "Press Release: Joerg Hornstein to Join Lundbeck as Chief Financial Officer and Head of Corporate Functions". Valby....
• [4] Lundbeckfonden. (4/4/22). "Press Release: Lundbeck Foundation Shifts into New Biotech Gear. New unit Raises Ambitions in Denmark – Lundbeckfonden BioCapital"....
• [5] Capsida Biotherapeutics Inc.. (12/7/21). "Press Release: Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO". Thousand Oaks, CA....
• [6] H. Lundbeck A/S. (11/29/21). "Press Release: Lundbeck Announces Changes to Executive Management". Valby....
• [7] H. Lundbeck A/S. (10/14/21). "Press Release: Lundbeck Receives Exclusive Rights to APB-A1, an Innovative Phase I-ready Bio-therapeutic for the Treatment of Neuroimmune Diseases from AprilBio"....
• [8] H. Lundbeck A/S. (8/5/20). "Press Release: Lundbeck Discontinues Phase II Proof of Concept Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia". Valby....
• [9] H. Lundbeck A/S. (3/27/20). "Press Release: Lundbeck Reports Headline Results from Phase IIa AMBLED study of Foliglurax in Parkinson’s Disease". Valby....
• [10] H. Lundbeck A/S. (3/27/20). "Press Release: Lundbeck Announces Phase IIa Study Results of Lu AG06466 in Adults with Tourette Syndrome". Valby....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.